Recovery of kidney function following delayed use of theralite™ dialyzer in a patient with myeloma cast nephropathy

3Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.
Get full text

Abstract

We report the case of a 60- year- old man who presented with newly diagnosed multiple myeloma complicated by biopsy-proven acute cast nephropathy, requiring hemodialysis, plasmapheresis and chemotherapy. After remaining dialysis dependent for 5 weeks, a high cut-off (HCO) dialyzer, intended to use for the removal of plasma substances with a molecular weight of up to 45 kDa such as free light chains, was introduced to his outpatient 4-hour hemodialysis regimen with an increase in treatment frequency to 4 sessions per week. Following 6 weeks of dialysis with the HCO dialyzer, serum levels of free κ light chains declined by more than 75%. Concurrently, he recovered kidney function and discontinued dialysis. He subsequently received a successful autologous stem-cell transplant. We discuss the potential merit of using the HCO dialyzer late in the course of the care of patients with myeloma cast nephropathy who are dialysis dependent. © 2013 Dustri-Verlag Dr. K. Feistle.

Cite

CITATION STYLE

APA

Dahal, K., Shastri, S., Narayanasami, U., Bijol, V., Rider, K., Strom, J. A., & Jaber, B. L. (2013). Recovery of kidney function following delayed use of theraliteTM dialyzer in a patient with myeloma cast nephropathy. Clinical Nephrology, 79(4), 318–322. https://doi.org/10.5414/CN107357

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free